Literature DB >> 2670645

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.

A Dunaif1, K R Segal, W Futterweit, A Dobrjansky.   

Abstract

Hyperinsulinemia secondary to a poorly characterized disorder of insulin action is a feature of the polycystic ovary syndrome (PCO). However, controversy exists as to whether insulin resistance results from PCO or the obesity that is frequently associated with it. Thus, we determined in vivo insulin action on peripheral glucose utilization (M) and hepatic glucose production (HGP) with the euglycemic glucose-clamp technique in obese (n = 19) and nonobese (n = 10) PCO women and age- and body-composition-matched normal ovulatory women (n = 11 obese and n = 8 nonobese women). None had fasting hyperglycemia. Two obese PCO women had diabetes mellitus, established with an oral glucose tolerance test; no other women had impairment of glucose tolerance. However, the obese PCO women had significantly increased fasting and 2-h glucose levels after an oral glucose load and increased basal HGP compared with their body-composition-matched control group. There were statistically significant interactions between obesity and PCO in fasting glucose levels and basal HGP (P less than .05). Steady-state insulin levels of approximately 100 microU/ml were achieved during the clamp. Insulin-stimulated glucose utilization was significantly decreased in both PCO groups whether expressed per kilogram total weight (P less than .001) or per kilogram fat free mass (P less than .001) or when divided by the steady-state plasma insulin (l) level (M/l, P less than .001). There was residual HGP in 4 of 15 obese PCO, 0 of 11 obese normal, 2 of 10 nonobese PCO, and 0 of 8 nonobese normal women. The metabolic clearance rate of insulin did not differ in the four groups. We conclude that 1) PCO women have significant insulin resistance that is independent of obesity, changes in body composition, and impairment of glucose tolerance, 2) PCO and obesity have a synergistic deleterious effect on glucose tolerance, 3) hyperinsulinemia in PCO is not the result of decreased insulin clearance, and 4) PCO is associated with a unique disorder of insulin action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670645     DOI: 10.2337/diab.38.9.1165

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  315 in total

Review 1.  Multiple signal transduction pathways regulate ovarian steroidogenesis.

Authors:  Jennifer R Wood; Jerome F Strauss
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

Review 2.  Screening for diabetes in pregnancy.

Authors:  S Virjee; S Robinson; D G Johnston
Journal:  J R Soc Med       Date:  2001-10       Impact factor: 5.344

3.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

4.  Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis.

Authors:  Song-Tao Tang; Chang-Jiang Wang; Hai-Qin Tang; Wen-Jia Peng; You-Min Wang; Qiu Zhang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 5.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

6.  Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.

Authors:  Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

7.  Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.

Authors:  Miro Šimun Alebić; Tomislav Bulum; Nataša Stojanović; Lea Duvnjak
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

8.  Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study.

Authors:  Zeki Yesilova; Cagatay Oktenli; S Yavuz Sanisoglu; Ugur Musabak; Erdinc Cakir; Metin Ozata; Kemal Dagalp
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

Review 9.  Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Vishnu Sundaresh; Amy T Wang; Patricia J Erwin; Corrine Welt; David Ehrmann; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

10.  Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.

Authors:  C M Bruns; S T Baum; R J Colman; D A Dumesic; J R Eisner; M D Jensen; L D Whigham; D H Abbott
Journal:  Int J Obes (Lond)       Date:  2007-05-01       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.